Precision BioSciences has patent protection for the engineered meganucleases process it uses under a license from Duke University, the company announced Tuesday.

Patent 8,021,867, awarded to the university, claims engineered meganucleases with altered DNA-cleavage specificity as well as modified DNA-binding affinity and/or modified dimerization properties, the company said.

“We believe that this patent grant strengthens Precision’s leadership position in the field of engineered meganucleases,” stated Derek Jantz, vice president of scientific development at Precision.

Precision’s proprietary Directed Nuclease Editor™ (DNE) technology enables the production of custom genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.